{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:42:37Z","timestamp":1790404957981,"version":"4.1.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:00:00Z","timestamp":1437091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0131651","type":"journal-article","created":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T14:08:17Z","timestamp":1437142097000},"page":"e0131651","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02300623","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Omar","family":"Sued","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nicol\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Manzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ag\u00fcero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Claramonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Tuset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pumarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gallart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,7,17]]},"reference":[{"issue":"17","key":"ref1","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1097\/00002030-200012010-00003","article-title":"Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection","volume":"14","author":"GR Kaufmann","year":"2000","journal-title":"AIDS"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1086\/314880","article-title":"Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia","volume":"180","author":"JJ Zaunders","year":"1999","journal-title":"J Infect Dis"},{"issue":"18","key":"ref3","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/00002030-200012220-00001","article-title":"Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection","volume":"14","author":"S Yerly","year":"2000","journal-title":"AIDS"},{"key":"ref4","article-title":"Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts","author":"L Hocqueloux","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.193.2.169","article-title":"Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection","volume":"193","author":"M Altfeld","year":"2001","journal-title":"J Exp Med"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1073\/pnas.97.7.3382","article-title":"Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes","volume":"97","author":"A Oxenius","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6803","key":"ref7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/35035103","article-title":"Immune control of HIV-1 after early treatment of acute infection","volume":"407","author":"ES Rosenberg","year":"2000","journal-title":"Nature"},{"issue":"5342","key":"ref8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1126\/science.278.5342.1447","article-title":"Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia","volume":"278","author":"ES Rosenberg","year":"1997","journal-title":"Science"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1758-2652-14-28","article-title":"HIV treatment for prevention","volume":"14","author":"J Ambrosioni","year":"2011","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"MS Cohen","year":"2011","journal-title":"N Engl J Med"},{"issue":"9135","key":"ref11","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0140-6736(05)60532-6","article-title":"Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study","volume":"352","author":"M Plana","year":"1998","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fimmu.2013.00162","article-title":"Lessons to be Learned from Natural Control of","volume":"4","author":"D Shasha","year":"2013","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fimmu.2013.00095","article-title":"Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease","volume":"4","author":"J Zaunders","year":"2013","journal-title":"Front Immunol"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1056\/NEJM199905273402114","article-title":"Control of HIV despite the discontinuation of antiretroviral therapy","volume":"340","author":"J Lisziewicz","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1172\/JCI7371","article-title":"HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy","volume":"104","author":"GM Ortiz","year":"1999","journal-title":"J Clin Invest"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archinte.163.10.1220","article-title":"A prospective trial of structured treatment interruptions in human immunodeficiency virus infection","volume":"163","author":"C Fagard","year":"2003","journal-title":"Arch Intern Med"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1086\/506364","article-title":"Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068","volume":"194","author":"JM Jacobson","year":"2006","journal-title":"J Infect Dis"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pmed.0010064","article-title":"Randomized, controlled trial of therapy interruption in chronic HIV-1 infection","volume":"1","author":"E Papasavvas","year":"2004","journal-title":"PLoS Med"},{"issue":"5496","key":"ref19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1126\/science.290.5496.1591","article-title":"Control of SIV rebound through structured treatment interruptions during early infection","volume":"290","author":"F Lori","year":"2000","journal-title":"Science"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1471-4906(02)02297-4","article-title":"STI and beyond: the prospects of boosting anti-HIV immune responses","volume":"23","author":"TM Allen","year":"2002","journal-title":"Trends Immunol"},{"issue":"5493","key":"ref21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1126\/science.290.5493.946","article-title":"AIDS. Boosting immunity to HIV\u2014can the virus help?","volume":"290","author":"B Autran","year":"2000","journal-title":"Science"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0952-7915(02)00359-X","article-title":"Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection","volume":"14","author":"RT Gandhi","year":"2002","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1371\/journal.pmed.0010036","article-title":"Limited durability of viral control following treated acute HIV infection","volume":"1","author":"DE Kaufmann","year":"2004","journal-title":"PLoS Med"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1097\/QAD.0b013e32833b61ba","article-title":"Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection","volume":"24","author":"L Hocqueloux","year":"2010","journal-title":"AIDS"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study","volume":"9","author":"A Saez-Cirion","year":"2013","journal-title":"PLoS Pathog"},{"issue":"4856","key":"ref26","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications","volume":"240","author":"KA Smith","year":"1988","journal-title":"Science"},{"issue":"19","key":"ref27","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1073\/pnas.93.19.10405","article-title":"Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity","volume":"93","author":"EL Jacobson","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"ref28","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199704243361716","article-title":"Interleukin-2 infusions in HIV-infected patients","volume":"336","author":"EL Jacobson","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"ref29","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/00002030-200102002-00006","article-title":"Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity","volume":"15","author":"KA Smith","year":"2001","journal-title":"AIDS"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"WM El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"issue":"15","key":"ref31","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/QAD.0b013e32835844d9","article-title":"Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial","volume":"26","author":"C Goujard","year":"2012","journal-title":"AIDS"},{"issue":"13","key":"ref32","first-page":"1726","article-title":"Use of highly sensitive assays for the evaluation of post-exposure HIV prophylaxis","volume":"12","author":"GA Schockmel","year":"1998","journal-title":"AIDS"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/modpathol.3800267","article-title":"Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence","volume":"18","author":"L Alos","year":"2005","journal-title":"Mod Pathol"},{"key":"ref34","unstructured":"REGA HIV-1 Subtyping Tool\u2014Version 2.0 Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dbpartners.stanford.edu\/RegaSubtyping\/\" xlink:type=\"simple\">http:\/\/dbpartners.stanford.edu\/RegaSubtyping\/<\/ext-link>. Accessed: May 2008."},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3851\/IMP2273","article-title":"HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy","volume":"17","author":"C Goujard","year":"2012","journal-title":"Antivir Ther"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa1110187","article-title":"Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy","volume":"368","author":"T Le","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"ref37","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1097\/QAD.0b013e32835805b6","article-title":"Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections","volume":"26","author":"J Ambrosioni","year":"2012","journal-title":"AIDS"},{"issue":"18","key":"ref38","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1097\/QAD.0b013e3283121c90","article-title":"Transmission networks of drug resistance acquired in primary\/early stage HIV infection","volume":"22","author":"BG Brenner","year":"2008","journal-title":"AIDS"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1468-1293.2012.01020.x","article-title":"Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study","volume":"13","author":"M Grijsen","year":"2012","journal-title":"HIV Med"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11904-013-0166-8","article-title":"Non-AIDS-defining cancers among HIV-infected patients","volume":"10","author":"J Cutrell","year":"2013","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"16","key":"ref41","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJMoa0903175","article-title":"Interleukin-2 therapy in patients with HIV infection","volume":"361","author":"D Abrams","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"e1001196","DOI":"10.1371\/journal.pmed.1001196","article-title":"No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial","volume":"9","author":"ML Grijsen","year":"2012","journal-title":"PLoS Med"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1110039","article-title":"Short-course antiretroviral therapy in primary HIV infection","volume":"368","author":"S Fidler","year":"2013","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0131651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T22:48:03Z","timestamp":1540334883000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0131651"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,17]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0131651","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,17]]}}}